Brokers Set Expectations for Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at Cantor Fitzgerald upped their FY2025 EPS estimates for Krystal Biotech in a report issued on Tuesday, November 4th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of $6.34 for the year, up from their prior estimate of $4.79. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. Cantor Fitzgerald also issued estimates for Krystal Biotech’s FY2026 earnings at $7.48 EPS.

Several other research firms have also weighed in on KRYS. Bank of America lifted their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Citigroup lifted their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a report on Tuesday. Chardan Capital lifted their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $228.14.

Krystal Biotech Trading Down 1.7%

NASDAQ:KRYS opened at $199.88 on Thursday. The firm has a market capitalization of $5.79 billion, a price-to-earnings ratio of 29.97 and a beta of 0.65. The firm’s fifty day simple moving average is $172.56 and its 200 day simple moving average is $153.49. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $212.98.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently made changes to their positions in the company. Brooklyn Investment Group increased its stake in shares of Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares during the period. Bessemer Group Inc. increased its stake in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the period. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech in the first quarter valued at approximately $29,000. AdvisorNet Financial Inc acquired a new stake in shares of Krystal Biotech in the third quarter valued at approximately $30,000. Finally, Hantz Financial Services Inc. increased its stake in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after purchasing an additional 179 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).